MCK — Q1 FY2027 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus sits at a manageable bar on adjusted EPS, but the biggest swing factor is whether GLP-1 distribution volumes rebounded sequentially after the Q4 FY2026 dip, and whether management's tone on the Medical-Surgical separation timeline remains confident.

Heading into Q1 FY2027, the bar on adjusted EPS looks achievable at $9.55 consensus vs. $8.26 in the prior-year quarter — a ~16% YoY hurdle that is consistent with management's full-year guidance of $43.80–$44.60 and the company's stated 14–16% organic growth trajectory. Management entered FY2027 from a position of strength, with CEO Brian Tyler explicitly flagging "significant momentum" and reaffirming long-term targets on the May 7 earnings call; tone has been unchanged and constructive since then, with no pre-announcement or guidance revision. Estimate revisions have been essentially flat since the post-print baseline (FY2027 EPS consensus moved from ~$44.27 to ~$44.25), suggesting the Street is comfortable with the guide rather than building in incremental upside. The stock has rallied ~10% since the Q4 print but has slightly lagged XLV (+12%), implying the market has not yet fully priced in a beat — the multiple remains below DCF-based fair value, leaving room for re-rating if execution is clean. The key wildcard is GLP-1 distribution volume trajectory: Q4 FY2026 saw a 4% sequential decline that spooked the revenue line (though management confirmed zero operating profit impact), and any sign of sequential recovery in Q1 — combined with continued strength in the Oncology & Multispecialty segment — could be the catalyst for a positive stock reaction.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar on adjusted EPS (~$9.55, +16% YoY) with the bigger swing factor being Oncology & Multispecialty operating profit, where the segment has consistently beaten expectations and any acceleration in provider network growth or acquisition contribution could drive upside. Revenue is a lower-quality signal given known IRA-related branded pricing headwinds and customer lapping effects that depress the top line without impacting operating profit.

Table 1 — Current Quarter Snapshot (Q1 FY2027)

Sources: Visible Alpha consensus and actuals data. Revenue, EPS Diluted - Operating($), Oncology & Multispecialty, North American Pharmaceutical, and RxTS segment operating profit figures sourced from Visible Alpha. FY2027 guidance ranges from MCK Q4 FY2026 earnings call (May 7, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters)

Top 2 KPIs: Adjusted EPS (Diluted - Operating) and Oncology & Multispecialty Segment Operating Profit

Pattern: MCK has beaten adjusted EPS consensus in 7 of the last 8 quarters, with the sole miss being a marginal -0.6% in Q3 FY2025; the Oncology segment has consistently beaten or met expectations in the quarters where VA consensus data is available, underscoring the reliability of that growth engine. Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance is unchanged since the May 7 earnings call — no post-earnings revisions, pre-announcements, or 8-K updates have altered the FY2027 framework; management tone remains confident and the Medical-Surgical separation is progressing on schedule, which is the most significant post-earnings development.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the post-print baseline — FY2027 EPS consensus has barely moved (-0.04%) and Q1 FY2027 EPS is essentially flat — suggesting the Street is comfortable with management's guidance framework and not building in incremental risk or upside; the slight downward drift in Q1 EPS (from $9.64 to $9.55) likely reflects seasonal cadence modeling rather than fundamental concern.

Source: Visible Alpha consensus and actuals data. Post-earnings baseline uses consensus as of May 12, 2026 (5 trading days after May 7, 2026 earnings release). The near-zero revision delta across all KPIs confirms the Street is anchored to management's guidance framework with no material divergence — this is a cushion, not a risk, as it leaves room for upside if execution is clean.

5. Stock Performance

Key Takeaway: MCK has rallied ~10% since the Q4 FY2026 earnings print (May 7, 2026) but has modestly lagged XLV (+12%), suggesting the stock's move has been driven primarily by sector-wide multiple expansion and healthcare sentiment rather than MCK-specific estimate revisions (which have been flat); the stock is not pricing in a beat, leaving asymmetric upside if Q1 execution is clean.

MCK vs. XLV (Health Care Select Sector SPDR) — Indexed to 100 at May 7, 2026 (Q4 FY2026 Earnings Date). Source: Yahoo Finance / Stock Price Data.

Key events since last earnings: June 9, 2026 — $2.25B Term B Loan closed for Medical-Surgical separation (8-K); July 1, 2026 — EVP Chief Strategy Officer Thomas Rodgers retirement announced, Ramesh Srinivasan appointed successor (8-K); July 22, 2026 — Annual Shareholder Meeting, all directors re-elected (8-K). The stock's strongest single-day move in the period was around July 16–17, 2026, when MCK surged to ~$841 from ~$796, likely driven by broader healthcare sector rotation and positive macro sentiment.

6. Material News & Developments

Key Takeaway: The most important post-earnings development is the successful closing of the $2.25B Term B Loan for the Medical-Surgical separation, which de-risks the capital structure and accelerates the ~$5B FY2027 share repurchase program — a direct EPS tailwind that the Street may be underweighting.

• June 9, 2026 — $2.25B Term B Loan Facility Closed (8-K): McKesson Medical-Surgical Top Holdings, Inc. closed a $2.25B senior secured Term B Loan due 2032 (SOFR + 2.25%), completing the stand-alone capital structure for the Medical-Surgical separation. Proceeds will be used to satisfy intercompany obligations with MCK parent and fund the ~$5B FY2027 share repurchase program. Implication: Accelerated buybacks are a direct EPS tailwind; weighted average diluted shares guided to 116–118M for FY2027.
• July 1, 2026 — EVP Chief Strategy Officer Retirement, New Appointment (8-K): Thomas L. Rodgers (EVP, Chief Strategy & Business Development Officer) announced retirement effective August 1, 2026. Ramesh Srinivasan appointed as EVP, Chief Strategy Officer effective August 1, 2026. Implication: Orderly transition; no disruption to strategic priorities. Rodgers was a named executive officer, so the change is notable but management flagged it as planned.
• July 22, 2026 — Annual Shareholder Meeting (8-K): All 11 director nominees re-elected; Deloitte & Touche LLP ratified as auditor for FY2027; executive compensation approved on advisory basis (86.6M for vs. 7.7M against). CEO Brian Tyler received the lowest "for" vote among directors (86.8M), though still a clear majority. Implication: No governance surprises; routine outcome.
• May 29, 2026 — ASCO 2026 Research Presentation (Press Release): The US Oncology Network presented research at ASCO 2026 demonstrating how community practices are expanding patient access through APP-led models. Implication: Reinforces the clinical and operational differentiation of the US Oncology Network, supporting the premium valuation of the Oncology & Multispecialty segment.
• GLP-1 Market Dynamics (Ongoing): The U.S. GLP-1 obesity market reached an estimated $35B annualized run rate in Q1 2026, with tirzepatide (Zepbound) rapidly closing the market share gap with semaglutide (Wegovy). YoY prescription volume growth remains ~40% in new-to-brand prescriptions. Novo Nordisk reported Q2 2026 adjusted sales +7% at CER, driven by GLP-1 volume growth. Implication: Continued GLP-1 category growth is a distribution volume tailwind for MCK; the key question is whether Q1 FY2027 saw sequential recovery after Q4 FY2026's 4% sequential decline.
• May 7, 2026 — CFO Transition: Britt Vitalone retired after 20+ years (8+ as CFO); Kenny Cheung assumed CFO role effective May 29, 2026. Vitalone remains as strategic advisor supporting Medical-Surgical separation. Implication: Q1 FY2027 will be Kenny Cheung's first earnings call as CFO — investors will be listening for any change in tone or disclosure style.
• IRA Branded Pricing Headwinds (Ongoing): Management flagged that Q4 FY2026 saw the first wave of IRA-related branded pharmaceutical price declines, reducing revenue growth by ~3 percentage points with zero operating profit impact. Full-year FY2027 will lap these declines. Implication: Revenue will continue to be a noisy signal; operating profit is the right metric to watch.

7. Peer Commentaries — Read-Through

Key Takeaway: Peer commentary from Cencora (COR) and Cardinal Health (CAH) at the Bank of America Global Healthcare Conference (May 13, 2026) — the most relevant post-MCK-earnings peer commentary covering the current reporting quarter — is broadly constructive for MCK: both peers confirmed IRA-related branded pricing declines have zero operating profit impact, specialty pharma volumes are strong, and oncology is a high-growth area, all of which directly validate MCK's FY2027 guidance framework.

Note on scope: Only commentary from after MCK's last earnings (May 7, 2026) that speaks to current-quarter (Q1 FY2027, calendar Q2 2026) trends is included below. HSIC (Henry Schein) reported Q2 2026 earnings on August 4, 2026 but is primarily a dental/medical distribution company with limited read-through to MCK's pharmaceutical distribution and oncology businesses; key HSIC observations are noted where relevant.

Cencora (COR) — Bank of America Global Healthcare Conference, May 13, 2026

Cardinal Health (CAH) — Bank of America Global Healthcare Conference, May 13, 2026

Henry Schein (HSIC) — Q2 2026 Earnings, August 4, 2026 (Limited Read-Through)

HSIC reported Q2 2026 earnings on August 4, 2026 (the day before MCK's print). HSIC is primarily a dental and medical distribution company with limited direct overlap with MCK's pharmaceutical distribution and oncology businesses. However, two observations are relevant:

• Healthcare demand resilience: HSIC reported internal local currency sales growth of 4.6%, non-GAAP EPS growth of 15.5%, and stated that markets are "stable and durable" with "good underlying fundamentals." Patient volumes were not materially impacted by higher oil prices. This broad healthcare demand resilience is a positive read-through for MCK's distribution volumes.
• Operational leverage: HSIC's non-GAAP operating margin expanded 25 bps YoY, driven by gross margin expansion across all segments. This confirms that healthcare distribution businesses can expand margins even in a moderately growing volume environment — consistent with MCK's operating leverage narrative.
• No GLP-1 or pharma distribution commentary: HSIC does not distribute GLP-1s or specialty pharmaceuticals in the same way as MCK, so there is no direct read-through on those key MCK metrics.

Sources: COR and CAH commentary from Bank of America Global Healthcare Conference transcripts (May 13, 2026). HSIC commentary from Q2 2026 Earnings Call transcript (August 4, 2026).

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells stand out as a meaningful signal — the dominant activity since the May 7 earnings print consists of routine equity award grants (code A) and tax-withholding dispositions (code F) tied to vesting events, plus CEO Brian Tyler's 10b5-1 planned sales which are pre-scheduled and non-discretionary; the absence of any open-market buying is neutral, not bearish.

Summary: All open-market disposals (code S) by executives are under pre-scheduled 10b5-1 plans and are therefore non-discretionary — they carry no informational signal about management's view of the upcoming print. The most notable transaction is the 11,101 RSU grant to new CFO Kenny Cheung upon assuming the role (May 29, 2026), which aligns his interests with shareholders from day one. No open-market buys were recorded in the period, which is neutral given the stock's ~10% rally since earnings. Source: SEC Form 4 filings via Insider Transaction Data.